中国防痨杂志 ›› 2021, Vol. 43 ›› Issue (3): 222-227.doi: 10.3969/j.issn.1000-6621.2021.03.006
收稿日期:
2021-01-28
出版日期:
2021-03-10
发布日期:
2021-03-03
通信作者:
刘晓清
E-mail:liuxq@pumch.cn
基金资助:
ZHANG Li-fan*, MA Hui-min, ZHENG Wen-jie, ZHANG Feng-chun, LIU Xiao-qing()
Received:
2021-01-28
Online:
2021-03-10
Published:
2021-03-03
Contact:
LIU Xiao-qing
E-mail:liuxq@pumch.cn
摘要:
目的 了解中国部分地区应用肿瘤坏死因子(tumor necrosis factor,TNF)拮抗剂治疗的患者结核病预防性治疗情况。方法 搜集2014年3月至2016年2月中国东、中、西部13家三级甲等综合医院接诊的应用依那西普或英夫利西单抗治疗的类风湿关节炎(rheumatoid arthritis,RA)或强直性脊柱炎(ankylosing spondylitis,AS)患者作为研究对象,共981例。收集研究对象的性别、年龄、激素和免疫抑制剂使用情况、并发基础疾病情况、结核病既往史、结核分枝杆菌潜伏感染(LTBI)筛查情况、胸部X线摄片(简称“胸片”)或胸部CT扫描结果、结核病预防性治疗情况。分析应用TNF拮抗剂的RA或AS患者筛查LTBI和非活动性肺结核的比例,进行结核病预防性治疗的比例以及采用的治疗方案。结果 981例研究对象中应用依那西普者779例(79.4%),应用英夫利西单抗者202例(20.6%)。仅有25.7%(252/981)的研究对象进行LTBI筛查,阳性率为18.3%(46/252)。2.8%(27/981)的研究对象诊断为非活动性肺结核,其中,有结核病既往史者19例。712例(72.6%)研究对象进行了胸片检查和(或)胸部CT扫描,报告非活动性肺结核者13例(1.8%)。共15例研究对象进行了结核病预防性治疗;并发LTBI者中有6例(13.0%,6/46)进行结核病预防性治疗;诊断为非活动性肺结核者均未进行结核病预防性治疗。进行结核病预防性治疗者中,应用异烟肼单药预防方案者9例(60.0%,9/15),疗程1~18个月不等。结论 中国部分地区目前应用TNF拮抗剂治疗的RA或AS患者的LTBI筛查比例低,进行结核病预防性治疗比例低,预防对象选择标准不一且预防方案不规范。
张丽帆, 马慧敏, 郑文洁, 张奉春, 刘晓清. 我国部分地区肿瘤坏死因子拮抗剂使用人群的结核病预防性治疗情况分析[J]. 中国防痨杂志, 2021, 43(3): 222-227. doi: 10.3969/j.issn.1000-6621.2021.03.006
ZHANG Li-fan, MA Hui-min, ZHENG Wen-jie, ZHANG Feng-chun, LIU Xiao-qing. Analysis of prevention treatment for tuberculosis in tumor necrosis factor antagonist users in some regions of China[J]. Chinese Journal of Antituberculosis, 2021, 43(3): 222-227. doi: 10.3969/j.issn.1000-6621.2021.03.006
表1
15例使用TNF拮抗剂治疗的RA或AS患者的临床特征及结核病预防性治疗方案
患者 序号 | 性 别 | 年龄 (岁) | 诊断 | TNF 拮抗剂 | 应用 激素 | 应用免疫 抑制剂 | 基础病 | T-SPOT. TB检测 | TST 检测 | 结核病 既往史 | 非活动性 肺结核 | 预防性 治疗方案 | 总疗程 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 男 | 50 | RA | 英夫利 西单抗 | 是 | 甲氨蝶呤 | 无 | - | - | 无 | 无 | 异烟肼+ 利福喷丁 | 2个月 |
2 | 女 | 46 | RA | 依那西普 | 是 | 来氟米特 | 无 | - | - | 无 | 无 | 异烟肼+ 利福平 | 8个月 |
3 | 女 | 46 | RA | 依那西普 | 是 | 甲氨蝶呤 | 无 | - | - | 无 | 无 | 异烟肼 | 4个月 |
4 | 女 | 61 | RA | 依那西普 | 是 | 甲氨蝶呤; 来氟米特 | 无 | 阳性 | - | 无 | 无 | 异烟肼 | 不详 |
5 | 男 | 53 | RA | 依那西普 | 是 | 甲氨蝶呤; 来氟米特 | 无 | - | - | 无 | - | 异烟肼+ 利福平+ 乙胺丁醇+ 吡嗪酰胺 | 1个月 |
6 | 女 | 61 | RA | 依那西普 | 否 | 无 | 糖尿病 | - | - | 无 | 无 | 异烟肼 | 18个月 |
7 | 男 | 31 | AS | 依那西普 | 否 | 无 | 无 | 阳性 | - | 无 | 无 | 异烟肼 | 1个月 |
8 | 男 | 55 | AS | 依那西普 | 否 | 柳氮磺 胺吡啶 | 无 | - | 阳性 | 无 | 无 | 异烟肼 | 不详 |
9 | 女 | 24 | AS | 依那西普 | 否 | 无 | 无 | - | - | 无 | 无 | 异烟肼 | 1个月 |
10 | 男 | 53 | AS | 依那西普 | 否 | 无 | 无 | 阴性 | - | 无 | 无 | 异烟肼 | 1个月 |
11 | 男 | 20 | AS | 依那西普 | 是 | 柳氮磺 胺吡啶 | 无 | 阴性 | 阳性 | 无 | 无 | 异烟肼 | 不详 |
12 | 女 | 19 | AS | 依那西普 | 是 | 甲氨蝶呤;柳 氮磺胺吡啶 | 无 | - | - | 无 | 无 | 异烟肼+ 利福平+ 乙胺丁醇+ 吡嗪酰胺 | 6个月 |
13 | 男 | 45 | AS | 依那西普 | 是 | 柳氮磺胺吡啶 | 无 | - | - | 无 | - | 不详 | 不详 |
14 | 男 | 33 | AS | 依那西普 | 否 | 甲氨蝶呤;柳 氮磺胺吡啶 | 无 | 阳性 | - | 无 | 无 | 异烟肼 | 4个月 |
15 | 男 | 28 | AS | 依那西普 | 否 | 甲氨蝶呤;柳 氮磺胺吡啶 | 无 | 阳性 | - | 无 | - | 异烟肼+ 利福平 | 24个月 |
[1] |
LoBue PA, Mermin JH. Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA. Lancet Infect Dis, 2017,17(10):e327-e333. doi: 10.1016/S1473-3099(17)30248-7.
doi: 10.1016/S1473-3099(17)30248-7 URL pmid: 28495525 |
[2] |
Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol, 2007,34(4):706-711.
URL pmid: 17309133 |
[3] |
Gómez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum, 2003,48(8):2122-2127. doi: 10.1002/art.11137.
doi: 10.1002/art.11137 URL pmid: 12905464 |
[4] |
Koike R, Takeuchi T, Eguchi K, et al. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol, 2007,17(6):451-458. doi: 10.1007/s10165-007-0626-3.
doi: 10.1007/s10165-007-0626-3 URL |
[5] |
Favalli EG, Caporali R, Sinigaglia L, et al. Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology Ⅱ. Safety. Clin Exp Rheumatol, 2011,29(3 Suppl 66):S15-S27.
URL pmid: 21906424 |
[6] |
Bombardier C, Hazlewood GS, Akhavan P, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part Ⅱ safety. J Rheumatol, 2012,39(8):1583-1602. doi: 10.3899/jrheum.110207.
doi: 10.3899/jrheum.120165 URL |
[7] |
British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax, 2005,60(10):800-805. doi: 10.1136/thx.2005.046797.
doi: 10.1136/thx.2005.046797 URL pmid: 16055611 |
[8] | Beglinger C, Dudler J, Mottet C, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly, 2007,137(43/44):620-622. |
[9] | Center for Disease Control and Prevention. Latent tuberculosis infection: A guide for primary health care providers[EB/OL].[2021-01-28]. https://www.cdc.gov/tb/publications/ltbi/pdf/ltbibooklet508.pdf. |
[10] |
Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J, 2015,46(6):1563-1576. doi: 10.1183/13993003.01245-2015.
doi: 10.1183/13993003.01245-2015 URL pmid: 26405286 |
[11] | 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家建议组. 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识. 中华风湿病学杂志, 2013,17(8):508-512. doi: 10.3760/cma.j.issn.1007-7480.2013.08.002. |
[12] |
Roach DR, Bean AG, Demangel C, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol, 2002,168(9):4620-4627. doi: 10.4049/jimmunol.168.9.4620.
doi: 10.4049/jimmunol.168.9.4620 URL pmid: 11971010 |
[13] |
Vila-del Sol V, Díaz-Muñoz MD, Fresno M. Requirement of tumor necrosis factor alpha and nuclear factor-kappaB in the induction by IFN-gamma of inducible nitric oxide synthase in macrophages. J Leukoc Biol, 2007,81(1):272-283. doi: 10.1189/jlb.0905529.
URL pmid: 17035338 |
[14] |
Nocturne G, Boudaoud S, Pascaud J, et al. Impact of anti-TNF therapy on NK cells function and on immunosurveillance against B-cell lymphomas. J Autoimmun, 2017,80:56-64. doi: 10.1016/j.jaut.2017.02.001.
doi: 10.1016/j.jaut.2017.02.001 URL pmid: 28214146 |
[15] |
Miller EA, Ernst JD. Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed. J Clin Invest, 2009,119(5):1079-1082. doi: 10.1172/jci39143.
doi: 10.1172/jci39143 URL pmid: 19422095 |
[16] |
Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum, 2004,50(2):372-379. doi: 10.1002/art.20009.
doi: 10.1002/art.20009 URL pmid: 14872478 |
[17] |
Wallis RS, Broder M, Wong J, et al. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis, 2004,39(8):1254-1255. doi: 10.1086/424455.
doi: 10.1086/424455 URL pmid: 15486857 |
[18] |
Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum, 2005,52(7):1986-1992. doi: 10.1002/art.21137.
doi: 10.1002/art.21137 URL pmid: 15986370 |
[19] |
Wang Q, Wen Z, Cao Q. Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: A meta-analysis. Exp Ther Med, 2016,12(3):1693-1704. doi: 10.3892/etm.2016.3548.
doi: 10.3892/etm.2016.3548 URL pmid: 27588089 |
[20] |
Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody)versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase Ⅲ trial. ATTRACT Study Group. Lancet, 1999,354(9194):1932-1939. doi: 10.1016/s0140-6736(99)05246-0.
doi: 10.1016/s0140-6736(99)05246-0 URL pmid: 10622295 |
[21] |
Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum, 2005,52(6):1766-1772. doi: 10.1002/art.21043.
doi: 10.1002/art.21043 URL pmid: 15934089 |
[22] | World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management: annex 3: values and preferences for the management of latent tuberculosis infection: survey of populations affected by the recommendations. Geneva: World Health Organization, 2018. |
[23] | 边赛男, 刘晓清. γ-干扰素释放试验在免疫功能抑制人群中诊断结核分枝杆菌感染的应用. 中华实验和临床感染病杂志(电子版), 2017,11(2):117-120. doi: 10.3877/cma.j.issn.1674-1358.2017.02.003. |
[24] |
Grzybowski S, Fishaut H, Rowe J, et al. Tuberculosis among patients with various radiologic abnormalities, followed by the chest clinic service. Am Rev Respir Dis, 1971,104(4):605-608. doi: 10.1164/arrd.1971.104.4.605.
doi: 10.1164/arrd.1971.104.4.605 URL pmid: 5094062 |
[25] |
Nolan CM, Elarth AM. Tuberculosis in a cohort of Southeast Asian Refugees. A five-year surveillance study. Am Rev Respir Dis, 1988,137(4):805-809. doi: 10.1164/ajrccm/137.4.805.
doi: 10.1164/ajrccm/137.4.805 URL pmid: 3354985 |
[26] |
This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med, 2000,161(4 Pt 2):S221-S247. doi: 10.1164/ajrccm.161.supplement_3.ats600.
doi: 10.1164/ajrccm.161.supplement_3.ats600 URL pmid: 10764341 |
[27] |
Zhang CY, Zhao F, Xia YY, et al. Prevalence and risk factors of active pulmonary tuberculosis among elderly people in China: a population based cross-sectional study. Infect Dis Poverty, 2019,8(1):7. doi: 10.1186/s40249-019-0515-y.
doi: 10.1186/s40249-019-0515-y URL pmid: 30654836 |
[28] |
Xin H, Zhang H, Yang S, et al. 5-Year follow-up of active tuberculosis development from latent infection in rural China. Clin Infect Dis, 2020,70(5):947-950. doi: 10.1093/cid/ciz581.
doi: 10.1093/cid/ciz581 URL pmid: 31253988 |
[29] |
Gao L, Zhang H, Xin H, et al. Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study. Eur Respir J, 2018,52(6):1801470. doi: 10.1183/13993003.01470-2018.
doi: 10.1183/13993003.01470-2018 URL pmid: 30361241 |
[30] |
Gao L, Li X, Zhang H, et al. Incidence of active tuberculosis in rural China-Authors’ reply. Lancet infect Dis, 2018,18(2):145-146. doi: 10.1016/S1473-3099(18)30022-7.
doi: 10.1016/S1473-3099(18)30022-7 URL pmid: 29412964 |
[31] |
Wong SH, Gao Q, Tsoi KK, et al. Effect of immunosuppressive therapy on interferon γ release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax, 2016,71(1):64-72. doi: 10.1136/thoraxjnl-2015-207811.
doi: 10.1136/thoraxjnl-2015-207811 URL pmid: 26659461 |
[32] |
Puri AS, Desai D, Sood A, et al. Infliximab-induced tuberculosis in patients with UC: Experience from India-a country with high prevalence of tuberculosis. J Gastroenterol Hepatol, 2017,32(6):1191-1194. doi: 10.1111/jgh.13669.
doi: 10.1111/jgh.13669 URL pmid: 27893931 |
[33] |
Kedia S, Mouli VP, Kamat N, et al. Risk of tuberculosis in patients with inflammatory bowel disease on infliximab or adali-mumab is dependent on the local disease burden of tuberculosis: a systematic review and meta-analysis. Am J Gastroenterol, 2020,115(3):340-349. doi: 10.14309/ajg.0000000000000527.
doi: 10.14309/ajg.0000000000000527 URL pmid: 32032073 |
[34] |
Ye L, Chapman TP, Wen Z, et al. Targeted versus universal tuberculosis chemoprophylaxis in 1968 patients with inflammatory bowel disease receiving anti-TNF therapy in a tuberculosis endemic region. Aliment Pharmacol Ther, 2021,53(3):390-399. doi: 10.1111/apt.16130.
doi: 10.1111/apt.16130 URL pmid: 33314259 |
[35] | World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020. |
[1] | 马艳, 高微微. 今非昔比:重视复治肺结核的合理施治[J]. 中国防痨杂志, 2021, 43(4): 313-317. |
[2] | 邓国防. 《结核病与糖尿病共病的治疗管理专家共识》解读[J]. 中国防痨杂志, 2021, 43(4): 318-321. |
[3] | 舒薇, 戈启萍, 黄学锐, 马丽萍, 纪滨英, 陈瑜晖, 陈效友, 姜广路, 谢莉, 李波, 陈盛玉, 陈森林, 闫俊萍, 石莲, 陈玲, 黎友伦, 席秀娥, 刘倩颖, 闫兴录, 王飞, 王芙蓉, 吴湘, 张朋, 冷学艳, 曹文利, 张海晴, 崔洪哲, 杨澄清, 吴超, 李鹃, 李华, 孙玙贤, 张立杰, 谢仕恒, 宁宇佳, 田希忠, 杜建, 李亮, 高微微. 复治肺结核耐异烟肼患者和耐利福平患者治疗效果的分析[J]. 中国防痨杂志, 2021, 43(4): 322-327. |
[4] | 戈启萍, 杜建, 舒嶶, 马艳, 马丽萍, 赵彩燕, 陈瑜晖, 张立杰, 黄学锐, 韩喜琴, 陈盛玉, 王飞, 李波, 曹文利, 刘倩颖, 陈东进, 石莲, 王鑫, 黎友伦, 杨尚鹏, 彭章丽, 吴超, 欧阳兵, 王芙蓉, 李钋, 吴湘, 席秀娥, 冷学艳, 张海晴, 李华, 李鹃, 杨澄清, 张朋, 崔洪哲, 谢莉, 刘宇红, 李亮, 高微微. 优化方案治疗复治药物敏感肺结核的疗效评价[J]. 中国防痨杂志, 2021, 43(4): 328-334. |
[5] | 张立杰, 韩喜琴, 王敬萍, 陈瑜晖, 陈盛玉, 陈玲, 李波, 林明贵, 黎友伦, 石莲, 席秀娥, 马丽萍, 王鑫, 王飞, 赵彩燕, 王芙蓉, 陈森林, 吴湘, 李钋, 张朋, 冷学艳, 张海晴, 曹文利, 舒薇, 孙玙贤, 谢仕恒, 田希忠, 黄学锐, 杜建, 高微微. 痰菌量与复治菌阳肺结核治疗失败和复发的关系[J]. 中国防痨杂志, 2021, 43(4): 335-340. |
[6] | 梁瑞云, 方伟军, 任会丽, 黎惠如, 张晖, 李城城. 耐药肺结核伴空洞患者的CT表现特征分析[J]. 中国防痨杂志, 2021, 43(4): 341-345. |
[7] | 俞珊, 李志明, 许春霞, 王涛. 结核病患者外周血γ干扰素释放试验假阴性的相关因素分析[J]. 中国防痨杂志, 2021, 43(4): 346-351. |
[8] | 刘婷, 王亮, 杨梅. 耐多药肺结核患者外周血中性粒细胞抗结核活性的初步研究[J]. 中国防痨杂志, 2021, 43(4): 352-356. |
[9] | 张晨晨, 谭卫国, 郭卉欣, 黄新春, 陈燕梅, 魏文静. 结核分枝杆菌感染对痰液菌群结构的影响[J]. 中国防痨杂志, 2021, 43(4): 357-363. |
[10] | 白桦, 郭婧玮, 胡培磊, 易松林, 文佳, 刘丰平, 谭云洪, 白丽琼. 2014—2018年湖南省耐药监测点结核分枝杆菌耐药监测结果分析[J]. 中国防痨杂志, 2021, 43(4): 364-369. |
[11] | 王欢, 沈鑫, 陈静, 夏珍, 徐飚, 袁政安. 2008—2019年上海市非户籍人口肺结核流行病学特征分析[J]. 中国防痨杂志, 2021, 43(4): 370-377. |
[12] | 马志涛, 王娜, 吕阳, 胡伟宏, 陈昶, 何凡, 沈鑫, 刘效峰. 上海市宝山区肺结核患者心理状态及其影响因素分析[J]. 中国防痨杂志, 2021, 43(4): 378-384. |
[13] | 李智红, 顾侃凯, 姚晶, 张怀庆, 韩志英, 沈鑫, 陈静, 沈冰. 上海市中心城区某幼儿园一例肺结核患者密切接触者筛查情况分析[J]. 中国防痨杂志, 2021, 43(4): 385-390. |
[14] | 麦维兰江·阿不力米提, 地尔木拉提·吐孙, 刘振江, 西日扎提·马木提, 李冠贞, 欧喜超. 2016—2018年喀什地区初治涂阳肺结核患者治疗效果及其影响因素分析[J]. 中国防痨杂志, 2021, 43(4): 391-397. |
[15] | 周爽, 陈楠, 朱坤, 姜慧, 杨磊, 杜建. 互联网诊疗平台对结核病患者的复诊体验调查[J]. 中国防痨杂志, 2021, 43(4): 398-403. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||